RxDoctor Payments Data

Daniel Wegg, MD

General Practice · Winchester, INNPI 1013909241

Payments from drug & device makers

$655in general payments, 2019–2025

Across 28 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$186
  • AbbVie$153
  • Boston Scientific$103
  • Novo Nordisk$60
  • Otsuka America Pharmaceutical, Inc.$41
  • Exact Sciences$18
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$655 in reported general payments places this provider in the 70th percentile of 1,558 general practice providers in Indiana.

See all general practice providers in Indiana

Medicare billing

Part B allowed, 2024
$251,310
Medicare patients
562
Services billed
3,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$111,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,362
JardianceEmpagliflozin61$39,553
TrulicityDulaglutide28$36,538
XareltoRivaroxaban41$33,049
JanuviaSitagliptin Phosphate27$30,075
RybelsusSemaglutide25$28,669
LinzessLinaclotide45$27,523
OzempicSemaglutide12$13,131
VascepaIcosapent Ethyl33$12,781
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$11,426
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$10,696
DuleraMometasone/Formoterol15$7,483
Aripiprazole50$6,932
Breo ElliptaFluticasone/Vilanterol16$6,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$14$114,070147 claims
Novo NordiskRybelsus, Ozempic$60$41,80037 claims
Johnson & JohnsonXarelto$14$33,04941 claims
AbbVieLinzess$153$27,52345 claims
AstraZenecaSymbicort$186$3,80714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,558 general practice providers in Indiana.

Other general practice in Winchester

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →